Garuda's $10 Billion Comeback? Airline in Surprise Talks for Massive Boeing Deal
Warning! GuruFocus has detected 6 Warning Signs with BA.
Garuda is also considering bringing back the 737 Max 8a model it quietly returned to lessors during its $10 billion debt restructuring. The airline had previously tried to cancel a $4.8 billion order for 49 of these planes following the 2018 Lion Air crash and a second fatal incident involving Ethiopian Airlines. Now, with a $405 million loan in hand from Indonesia's sovereign wealth fund Danantara, Garuda is re-evaluating the aircraft's place in its fleetpossibly signaling a shift in sentiment toward Boeing's embattled jet.
It's still unclear whether this new round of discussions with Boeing reflects a fresh order or a repackaging of the original 49-plane deal. But either scenario could set the stage for Garuda's comeback story. Investors watching the region's aviation recovery may want to pay attentionthis could be more than just a fleet upgrade. It might be the first real sign of Indonesia repositioning itself on the global aviation map, with Garuda as the front-runner.
This article first appeared on GuruFocus.
登入存取你的投資組合
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite," said Peter DeYoung, CEO, Piramal Global Pharma. "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too." "By investing in Piramal Pharma Solutions' Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand," said Douglas Kling, COO, NewAmsterdam Pharma. "We are excited to continue growing alongside our trusted partner, Piramal Pharma Solutions, and thrilled about the potential for our collaboration to benefit countless patients around the globe." Patients aren't the only beneficiaries of this investment. Over the next five years, the suite is expected to create more than 20 new jobs at the Sellersville site, further contributing to the local economy and workforce. This investment underscores the commitment to continuous improvement shared by Piramal Pharma Solutions and NewAmsterdam Pharma. By adding the new production suite, both companies can operate with greater efficiency and capacity, ultimately bringing the FDC product, if approved, to more patients in need. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. The Company seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo : : : : : View original content to download multimedia: SOURCE Piramal Pharma Solutions View original content to download multimedia:
Bloomberg
12 minutes ago
- Bloomberg
Spurned by Trump, Modi Springs Into Action
Newsletter India Edition Trump's 50% tariff will hit India next week Welcome to India Edition, I'm Menaka Doshi. Join me each week for a ringside view of the billionaires, businesses and policy decisions behind India's rise as an emerging economic powerhouse. You can subscribe here, and share feedback with me here.
CNBC
12 minutes ago
- CNBC
CNBC Daily Open: Tech sell-off? Investors could just be taking profit and enjoying the summer
If you have any U.S. technology stocks in your portfolio (and let's face it, who doesn't?), you might want to look away. For the second day in a row, tech stocks dragged markets lower, with the Nasdaq Composite slipping 0.67%. Juggernauts such as Apple, Amazon and Alphabet were more meh-nificent than magnificent, falling more than 1%. Palantir — the standout S&P 500 stock, having more than doubled so far this year — had its sixth consecutive day in the red and lost its place among a ranking of the 20 most valuable U.S. companies. While Palantir's slide was partly triggered by a report from short seller Andrew Left's Citron Research, which called the company "detached from fundamentals and analysis," there was no single trigger for the broader pullback. Investors could have been spooked by OpenAI CEO Sam Altman's caution about an AI bubble forming, although some analysts dispute that assertion. "In our view the tech bull cycle will be well intact at least for another 2-3 years," said Wall Street tech bull Dan Ives. Or it could be something benign, like traders locking in profits. "Tech stocks," said Carol Schleif, chief market strategist at BMO Private Wealth, "have had an incredibly strong run – with some up over 80% since the early April lows." Summer, after all, is far from over. Some investors might have just wanted to cash out for another round of margaritas. Fed officials divided over inflation and employment worries. Central bank governors generally agreed there were risks on both sides. But a couple — breaking from the majority — saw the labor market woes as more pressing, according to minutes of the Fed's July meeting. No new solar or wind power projects, Trump says. Renewable energy projects will no longer receive approval, Trump posted Wednesday on Truth Social. His comment comes after the administration already tightened federal permitting last month. Meta Platforms freezes hiring artificial intelligence talent. The tech giant had in recent months been splashing out eye-watering amounts of money — up to $100 million on signing bonuses — to poach AI employees at other firms. But it appears that cash pool's left to dry for now. Fourth day of losses for the S&P 500. Technology stocks declined on Wednesday, with Palantir having its sixth straight losing day. Asia-Pacific markets were mostly lower Thursday — but Australia's S&P/ASX 200 rose to break the 9,000 level for the first time. [PRO] The Fed is expected to cut just as markets trade at highs. This is what tends to happen when both factors coincide, according to Goldman Sachs research. Red carpet for Putin, trade relief for China, penalties on India: Inside Trump's peculiar policy playbook U.S. President Donald Trump is pursuing an unusual strategy — courting Russian President Vladimir Putin, holding fire on Beijing, all the while turning the screws on India. Despite India being one of the earliest nations to engage in negotiations with the Trump administration, there is still no sign of it sealing a deal with America. New Delhi is now also staring at a secondary tariff of 25% or a "penalty" for its purchases of Russian oil that is set to come into effect later this month.
